TransMedics Group, Inc.TMDXEarnings & Financial Report
Nasdaq · Health Care · Electromedical & Electrotherapeutic Apparatus
TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 15.90% | 5.3M | ▲ +8.10pp | 2024-10-07 |
| The Vanguard Group | 10.77% | 3.6M | ▲ +5.06pp | 2024-10-04 |
| FMR LLC | 6.60% | 2.2M | ▼ -8.40pp | 2024-10-07 |
| Macquarie Group Limited | 4.67% | 1.5M | — | 2024-02-14 |
Insider Transactions
Net 90d: −$2.35M · buys $0 / sells $2.35MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-04 | David Weill | Director | Option exercise | 3.6K | $14.20 | $50.7K |
| 2026-03-04 | David Weill | Director | Sell (open market) | 3.6K | $146.82 | $524.3K |
| 2026-03-04 | Stephanie Lovell | Director | Sell (open market) | 1.2K | $149.62 | $178.5K |
| 2026-03-04 | Gerardo Hernandez | Chief Financial Officer | Option exercise | 1.3K | $77.12 | $102.1K |
| 2026-03-04 | Gerardo Hernandez | Chief Financial Officer | Sell (open market) | 1.3K | $147.21 | $194.9K |
| 2026-03-04 | Gerardo Hernandez | Chief Financial Officer | Option exercise | 5.9K | $69.84 | $412.9K |
| 2026-03-04 | Gerardo Hernandez | Chief Financial Officer | Sell (open market) | 5.9K | $147.21 | $870.3K |
| 2026-03-02 | Gerardo Hernandez | Chief Financial Officer | Sell (open market) | 375 | $139.12 | $52.2K |
| 2026-03-02 | Ranganath Anil P. | See remarks | Sell (open market) | 864 | $139.12 | $120.2K |
| 2026-03-02 | Nicholas Corcoran | See remarks | Sell (open market) | 3.0K | $139.12 | $412.6K |
1–10 of 11
Page 1 / 2